Medivation Inc. (MDVN1)

Sector:
HEALTH CARE
Industry:
HEALTH CARE
SIC:
BLANK CHECKS
CEO:
David T. Hung
Employees:
628
525 MARKET STREET, 36TH FLOOR, SAN FRANCISCO, CA 94105
415-543-3470

*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States.

Data derived from most recent annual or quarterly report
Market Cap 13.513 Billion Shares Outstanding165.929 Million Avg 30-day Volume 5.076 Million
P/E Ratio0.0 Dividend Yield0.0 EPS
Price to Revenue9.6829 Debt to Equity0.0418 EBITDA-247.206 Million
Price to Book Value18.635 Operating Margin-25.0394 Enterprise Value9.617 Billion
Current Ratio4.323 EPS Growth-1.761 Quick Ratio2.335
1 Yr BETA 0.9549 52-week High/Low 0.0 / Profit Margin-17.2421
Operating Cash Flow Growth31.8113 Altman Z-Score5.5645 Free Cash Flow to Firm -181.282 Million
View SEC Filings from MDVN1 instead.

View recent insider trading info

Funds Holding MDVN1 (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MDVN1 BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2016-09-28:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-09-02:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2016-08-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-07-29:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2016-07-06:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-07-05:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-06-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-06-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2016-06-24:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    YARNO WENDY L

    • Director
    No longer subject to file 2016-09-28 0

    FALBERG KATHRYN E

    • Director
    No longer subject to file 2016-09-28 0

    BLICKENSTAFF KIM D

    • Director
    No longer subject to file 2016-09-28 0

    POWELL ANDREW KENNETH WILLIAM SVP, GENERAL COUNSEL & CRP SEC

    • Officer
    No longer subject to file 2016-09-28 0

    HUNG DAVID PRESIDENT AND CEO

    • Officer
    • Director
    No longer subject to file 2016-09-28 0

    MACHADO PATRICK

    • Director
    No longer subject to file 2016-09-28 0

    VERNON W ANTHONY

    • Director
    No longer subject to file 2016-09-28 0

    SVORONOS DAWN

    • Director
    No longer subject to file 2016-09-28 0

    YANG TSELI LILY VP, FINANCE AND ACCOUNTING

    • Officer
    No longer subject to file 2016-09-28 0

    HIRMAND MOHAMMAD INTERIM CHIEF MEDICAL OFFICER

    • Officer
    No longer subject to file 2016-09-28 0

    KING MICHAEL L

    • Director
    No longer subject to file 2016-09-28 0

    MCCOURT MARION CHIEF OPERATING OFFICER

    • Officer
    No longer subject to file 2016-09-28 0

    JARRETT JENNIFER CHIEF FINANCIAL OFFICER

    • Officer
    No longer subject to file 2016-09-28 0

    BIERLY RICK CFO (FORMER)

    • Officer
    28,744 2016-05-05 0

    LOBACKI JOSEPH M CHIEF COMMERCIAL OFFICER

    • Officer
    19,365 2016-01-04 0

    TEMPLEMAN THOMAS SVP, PHARMACEUTICAL OPERATIONS

    • Officer
    22,720 2015-09-29 0

    RHODES JENNIFER J GC & CORPORATE SECRETARY

    • Officer
    11,090 2015-03-16 0

    SEELY LYNN CHIEF MEDICAL OFFICER

    • Officer
    0 2015-02-17 0

    ADAMS DANIEL

    • Director
    5,807 2014-06-27 0

    KELSEY STEPHEN MICHAEL SVP OF NEW PROJECTS

    • Officer
    0 2014-02-18 0

    COHEN CHERYL CHIEF COMMERCIAL OFFICER

    • Officer
    0 2014-02-18 0

    BAILEY GREGORY

    • Director
    691,101 2012-10-30 0

    QVT ASSOCIATES GP LLC

    • 10% Owner
    No longer subject to file 2011-06-07 0

    PALEKAR ROHAN CHIEF COMMERCIAL OFFICER

    • Officer
    16,666 2011-04-20 0

    PROTTER ANDREW A VP, PRECLINICAL DEVELOPMENT

    • Officer
    0 2008-10-31 0

    CHAKRAVARTY SARVAJIT VP OF MEDICINAL CHEMISTRY

    • Officer
    0 2008-10-31 0

    HARBINGER CAPITAL PARTNERS MASTER FUND I, LTD.

    HARBINGER CAPITAL PARTNERS OFFSHORE MANAGER, L.L.C.

    HMC INVESTORS, L.L.C.

    HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS FUND, L.P.

    HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS GP, LLC

    HMC - NEW YORK, INC.

    HARBERT MANAGEMENT CORP

    FALCONE PHILIP

    HARBERT RAYMOND J

    LUCE MICHAEL D

    • 10% Owner
    • *SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS
    No longer subject to file 2008-10-03 0

    HARBINGER CAPITAL PARTNERS MASTER FUND I, LTD.

    HARBINGER CAPITAL PARTNERS OFFSHORE MANAGER, L.L.C.

    HMC INVESTORS, L.L.C.

    FALCONE PHILIP

    HARBERT RAYMOND J

    LUCE MICHAEL D

    • 10% Owner
    • *SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS*SEE REMARKS
    3,159,000 2008-08-01 0

    HARBERT MANAGEMENT CORP

    FALCONE PHILIP

    HARBERT RAYMOND J

    LUCE MICHAEL D

    • 10% Owner
    2,995,000 2007-12-05 0

    MARXE AUSTIN W & GREENHOUSE DAVID M

    • 10% Owner
    2,689,664 2007-10-11 0

    KNOLL CAPITAL MANAGEMENT, LP

    KNOLL FRED

    • 10% Owner
    0 2006-05-16 0

    GORLIN STEVE

    • Director
    • 10% Owner
    992,873 2005-12-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments